Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment
暂无分享,去创建一个
I. U. Haq | C. McCabe | L. Ramsay | D. M. Pickin | P. Jackson | W. W. Yeo | I. Haq | P. Jackson | N. Payne | C. McCabe | L. E. Ramsay | C. Mccabe | Wilfred W. Yeo | Christopher McCabe
[1] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[2] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[3] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[4] J. McMurray,et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin , 1997, BMJ.
[5] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[6] M. Johannesson,et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.
[7] N. Payne,et al. Variations in use of cardiology services in a health authority: comparison of coronary artery revascularisation rates with prevalence of angina and coronary mortality , 1997, BMJ.
[8] K. Goa,et al. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. , 1997, PharmacoEconomics.
[9] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[10] T. Lancet,et al. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996, The Lancet.
[11] L. Ramsay,et al. The Sheffield table for primary prevention of coronary heart disease: corrected , 1996, The Lancet.
[12] S. Grundy. More on pravastatin and coronary disease. , 1996, The New England journal of medicine.
[13] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[14] L. Ramsay,et al. Lipid-lowering for prevention of coronary heart disease: what policy now? , 1996, Clinical science.
[15] L. Ramsay,et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.
[16] C. Furberg,et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. , 1996, The American journal of cardiology.
[17] H Wedel,et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) , 1996, European heart journal.
[18] W. Hollingworth,et al. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population , 1996, BMJ.
[19] G. Thorgeirsson,et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.
[20] J. Myers,et al. Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia , 1996 .
[21] I. U. Haq,et al. Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease , 1995, The Lancet.
[22] R. Beaglehole,et al. Evidence-based management of dyslipidaemia , 1995, The Lancet.
[23] L. Coupal,et al. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.
[24] M. Abrahamowicz,et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study , 1995, BMJ.
[25] L. Coupal,et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. , 1995, JAMA.
[26] D. Sackett,et al. The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.
[27] C. Harries,et al. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. , 1995, The British journal of general practice : the journal of the Royal College of General Practitioners.
[28] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[29] L. Martens,et al. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. , 1994, Clinical therapeutics.
[30] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice , 1994 .
[31] P. Poole‐Wilson,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.
[32] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[33] A. B. Prasad,et al. British National Formulary , 1994 .
[34] G. Smith,et al. Commentary: Statistical problems , 1994 .
[35] A Briggs,et al. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.
[36] L. Wilkins. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .
[37] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[38] L. Wilkins,et al. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.
[39] P. Milner,et al. Local confidential inquiry into avoidable factors in deaths from stroke and hypertensive disease. , 1993, BMJ.
[40] A. L. Cochrane,et al. Effectiveness and efficiency: random reflections on health services , 1972 .